AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: LON:AZN
- CUSIP: N/A
- Web: www.astrazeneca.com/
Capitalization:- Market Cap: £54.75 billion
- Outstanding Shares: 1,266,000,000
Average Prices:- 50 Day Moving Avg: GBX 5,187.89
- 200 Day Moving Avg: GBX 4,861.95
- 52 Week Range: GBX 3,996 - GBX 5,520
P/E:- Trailing P/E Ratio: 16.20
- P/E Growth: 3.29
Sales & Book Value:- Annual Revenue: £22.29 billion
- Price / Sales: 2.46
- Book Value: GBX 10.26 per share
- Price / Book: 4.22
Dividend:
Profitability:- EBIDTA: £5.84 billion
- Net Margins: 9.47%
- Return on Equity: 15.47%
- Return on Assets: 3.33%
Misc:- Average Volume: 2.15 million shs.
Frequently Asked Questions for AstraZeneca plc (LON:AZN)
What is AstraZeneca plc's stock symbol?
AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."
How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?
AstraZeneca plc declared a dividend on Thursday, July 27th. Shareholders of record on Thursday, August 10th will be given a dividend of GBX 68.90 per share on Monday, September 11th. This represents a yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th. The official announcement can be viewed at this link. View AstraZeneca plc's Dividend History.
Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?
20 equities research analysts have issued 1 year price objectives for AstraZeneca plc's stock. Their forecasts range from GBX 3,900 to GBX 6,500. On average, they anticipate AstraZeneca plc's stock price to reach GBX 5,257.16 in the next twelve months. View Analyst Ratings for AstraZeneca plc.
Who are some of AstraZeneca plc's key competitors?
Some companies that are related to AstraZeneca plc include Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), GlaxoSmithKline plc (GSK), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG) and Horizon Pharma PLC (HZNP).
Who are AstraZeneca plc's key executives?
AstraZeneca plc's management team includes the folowing people:
- Pascal Soriot, Executive Director and Chief Executive Officer
- Marc Dunoyer, Executive Director, Chief Financial Officer
- Fiona Cicconi, Executive Vice-President, Human Resources
- Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
- Pam P. Cheng, Executive Vice President - Operations and Information Technology
- Ruud Dobber, Executive Vice President, North America
- Bahija Jallal Ph.D., Executive Vice President, MedImmune
- Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
- Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
- Leon Wang, Executive Vice President - Asia Pacific
How do I buy AstraZeneca plc stock?
Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is AstraZeneca plc's stock price today?
One share of AstraZeneca plc stock can currently be purchased for approximately GBX 4,325.
MarketBeat Community Rating for AstraZeneca plc (LON AZN)MarketBeat's community ratings are surveys of what our community members think about AstraZeneca plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AstraZeneca plc (LON:AZN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 9 Hold Ratings, 9 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.35) |
| Consensus Price Target: | GBX 5,257.16 |
Analysts' Ratings History for AstraZeneca plc (LON:AZN)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 7/27/2017 | S&P Global | Set Price Target | Neutral | GBX 4,500 |  |
| 7/27/2017 | Shore Capital | Reiterated Rating | Hold | | |
| 7/27/2017 | Liberum Capital | Reiterated Rating | Buy | GBX 5,500 | |
| 7/26/2017 | Barclays PLC | Reiterated Rating | Overweight | GBX 6,300 | |
| 7/21/2017 | J P Morgan Chase & Co | Reiterated Rating | Neutral | | |
| 7/21/2017 | BNP Paribas | Reiterated Rating | Neutral | | |
| 7/14/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell | GBX 3,900 | |
| 7/13/2017 | Kepler Capital Markets | Reiterated Rating | Buy | GBX 5,500 | |
| 7/13/2017 | Citigroup Inc. | Reiterated Rating | Buy | GBX 6,000 | |
| 7/12/2017 | Jefferies Group LLC | Lower Price Target | Hold | GBX 5,500 -> GBX 5,300 | |
| 7/4/2017 | HSBC Holdings plc | Downgrade | Reduce | GBX 4,500 | |
| 6/30/2017 | Deutsche Bank AG | Reiterated Rating | Buy | GBX 5,700 | |
| 6/23/2017 | Morgan Stanley | Reiterated Rating | Overweight | GBX 5,600 | |
| 6/19/2017 | Credit Suisse Group | Reiterated Rating | Neutral | GBX 5,000 | |
| 5/26/2017 | Investec | Boost Price Target | Hold | GBX 4,600 -> GBX 5,000 | |
| 5/17/2017 | Berenberg Bank | Boost Price Target | Buy | GBX 5,670 -> GBX 5,850 | |
| 4/28/2017 | Sanford C. Bernstein | Set Price Target | Neutral | GBX 4,736 | |
| 4/3/2017 | Beaufort Securities | Reiterated Rating | Hold | | |
| 3/23/2017 | Societe Generale | Reiterated Rating | Buy | | |
| 2/28/2017 | Bryan, Garnier & Co | Reiterated Rating | Buy | GBX 5,400 | |
| 6/24/2016 | Independent Research GmbH | Set Price Target | Sell | GBX 3,650 | |
| 5/10/2016 | Oddo Securities | Reiterated Rating | Buy | GBX 5,400 | |
| 5/5/2016 | Charles Stanley | Upgrade | Strong-Buy | | |
| 3/24/2016 | Natixis | Reiterated Rating | Neutral | GBX 4,456 | |
| 3/23/2016 | Nomura | Lower Price Target | Hold | GBX 4,880 -> GBX 4,350 | |
| 2/12/2016 | Baader Bank | Reiterated Rating | Hold | GBX 4,400 | |
| 2/9/2016 | AlphaValue | Upgrade | Buy | GBX 4,640 | |
| 2/4/2016 | S&P Equity Research | Set Price Target | Neutral | GBX 4,500 | |
| 2/2/2016 | Handelsbanken | Reiterated Rating | Accumulate | GBX 5,220.30 | |
| 1/28/2016 | Pareto Securities | Reiterated Rating | Sell | GBX 3,855.35 | |
| 1/27/2016 | Swedbank | Reiterated Rating | Buy | GBX 5,115.47 | |
| 1/13/2016 | Nordea Equity Research | Reiterated Rating | Hold | GBX 4,698.35 | |
(Data available from 7/27/2015 forward)
Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for AstraZeneca plc (LON:AZN)Current Year EPS Consensus Estimate: $3.69 EPS
Dividend History by Quarter for AstraZeneca plc (LON AZN)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/27/2017 | | GBX 68.90 | 1.35% | 8/10/2017 | 8/10/2017 | 9/11/2017 |
| 2/2/2017 | | GBX 150.20 | 3.52% | 2/16/2017 | 2/16/2017 | 3/20/2017 |
| 7/28/2016 | | GBX 68.70 | 1.37% | 8/11/2016 | 8/11/2016 | 9/12/2016 |
| 2/4/2016 | | GBX 131 | 3.16% | 2/18/2016 | 2/18/2016 | 3/21/2016 |
| 7/30/2015 | | GBX 57.50 | 1.33% | 8/13/2015 | 8/13/2015 | 9/14/2015 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)Insider Trades by Quarter for AstraZeneca plc (LON:AZN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/27/2015 | Courtois,Jean-Philippe | Insider | Buy | 900 | GBX 4,423 | £39,807 | |
| 8/28/2015 | Soriot,Pascal | Insider | Buy | 76,300 | GBX 3,960 | £3,021,480 | |
| 5/7/2015 | Marc Dunoyer | Insider | Buy | 10,000 | GBX 4,397 | £439,700 | |
| 4/30/2015 | Ann Cairns | Insider | Buy | 1,100 | GBX 4,455 | £49,005 | |
| 4/29/2015 | Shriti Vadera | Insider | Buy | 3,500 | GBX 4,563 | £159,705 | |
| 4/28/2015 | Graham Chipchase | Insider | Buy | 1,100 | GBX 4,606 | £50,666 | |
| 4/27/2015 | Bruce Burlington | Insider | Buy | 600 | GBX 4,662 | £27,972 | |
(Data available from 1/1/2013 forward)
Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
| Source: |
|
| Date | Headline |
|---|
 | AstraZeneca plc (AZN) Given a GBX 4,500 Price Target by S&P Global Analysts
www.americanbankingnews.com - July 27 at 4:05 PM |
 | AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment
investorplace.com - July 27 at 12:10 PM |
| AstraZeneca plc to Issue Dividend of GBX 68.90 (AZN)
www.americanbankingnews.com - July 27 at 11:16 AM |
 | Why Is AstraZeneca Sinking Today?
feeds.benzinga.com - July 27 at 10:20 AM |
| AstraZeneca plc (AZN) Given a GBX 5,150 Price Target at UBS AG
www.americanbankingnews.com - July 27 at 6:20 AM |
 | Is Lower Revenue in the Cards for AstraZeneca’s 2Q17?
finance.yahoo.com - July 26 at 9:59 PM |
 | AstraZeneca Receives EU Approval For Faslodex Breast Cancer Drug
www.morningstar.co.uk - July 26 at 4:57 PM |
| AstraZeneca plc (AZN) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - July 22 at 12:18 PM |
| AstraZeneca plc (LON:AZN) Receives "Neutral" Rating from BNP Paribas
www.americanbankingnews.com - July 21 at 8:16 AM |
| AstraZeneca plc (AZN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 21 at 7:36 AM |
 | Chaos At AstraZeneca - Seeking Alpha
seekingalpha.com - July 19 at 10:33 PM |
| AstraZeneca plc (LON:AZN) to Release Earnings on Wednesday
www.americanbankingnews.com - July 19 at 2:58 AM |
 | AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise - Nasdaq
www.nasdaq.com - July 17 at 9:39 PM |
| AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
finance.yahoo.com - July 17 at 9:38 PM |
| CEO departures not always bad for companies: Cramer
finance.yahoo.com - July 17 at 9:38 PM |
 | AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot - TheStreet.com
www.thestreet.com - July 14 at 11:13 PM |
| Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter - TheStreet.com
www.thestreet.com - July 14 at 6:11 PM |
| Goldman Sachs Group, Inc. (The) Reiterates GBX 3,900 Price Target for AstraZeneca plc (AZN)
www.americanbankingnews.com - July 14 at 11:37 AM |
| BUZZ-US STOCKS ON THE MOVE-Yandex, AstraZeneca, Target, Teva, Delta Air Lines - Nasdaq
www.nasdaq.com - July 13 at 10:18 PM |
| [$$] Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going?
finance.yahoo.com - July 13 at 10:18 PM |
| Analyst Wonders If AstraZeneca's CEO Would Be A Fit At Teva
feeds.benzinga.com - July 13 at 5:28 PM |
 | Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going?
www.wsj.com - July 13 at 5:13 PM |
| AstraZeneca is Oversold - Nasdaq
www.nasdaq.com - July 13 at 5:13 PM |
| Is Parting Such Sweet Soriot For AstraZeneca? - Seeking Alpha
seekingalpha.com - July 13 at 5:13 PM |
| AstraZeneca plc (AZN) Earns "Hold" Rating from Shore Capital
www.americanbankingnews.com - July 13 at 3:06 PM |
| AstraZeneca plc's (LON:AZN) Neutral Rating Reaffirmed at J P Morgan Chase & Co
www.americanbankingnews.com - July 13 at 6:58 AM |
 | London Markets: FTSE 100 slips as AstraZeneca slides
www.marketwatch.com - July 13 at 5:16 AM |
| Performance of AstraZeneca Stock in 2Q17
finance.yahoo.com - July 10 at 4:22 PM |
| AstraZeneca plc (LON:AZN) Stock Rating Reaffirmed by Citigroup Inc.
www.americanbankingnews.com - July 9 at 9:40 PM |
| Barclays PLC Boosts AstraZeneca plc (AZN) Price Target to GBX 6,300
www.americanbankingnews.com - July 3 at 1:33 PM |
| AstraZeneca plc (AZN) Receives "Buy" Rating from Deutsche Bank AG
www.americanbankingnews.com - July 1 at 10:34 PM |
| Analyst Recommendations for AstraZeneca in June 2017
finance.yahoo.com - June 30 at 9:27 PM |
| Canada's top court hands patent win to pharmaceutical companies - Nasdaq
www.nasdaq.com - June 30 at 4:22 PM |
| AstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 26 at 7:44 AM |
| AstraZeneca plc (AZN) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - June 23 at 7:14 AM |
| [$$] Repare Therapeutics Grabs $68 Million, Targets 'Synthetic Lethality' in Cancer
finance.yahoo.com - June 22 at 8:56 PM |
| AstraZeneca plc (AZN) Receives Neutral Rating from Credit Suisse Group
www.americanbankingnews.com - June 19 at 11:52 PM |
| AstraZeneca plc (AZN) Given Hold Rating at Shore Capital
www.americanbankingnews.com - June 17 at 10:58 PM |
| Jefferies Group LLC Boosts AstraZeneca plc (AZN) Price Target to GBX 5,500
www.americanbankingnews.com - June 17 at 1:38 PM |
| AstraZeneca plc (AZN) Given Buy Rating at Deutsche Bank AG
www.americanbankingnews.com - June 17 at 1:02 PM |
 | AstraZeneca Presents New Data On Farxiga
www.rttnews.com - June 12 at 4:48 PM |
| December 15th Options Now Available For AstraZeneca (AZN)
www.nasdaq.com - June 12 at 4:48 PM |
| When to Roll Over
finance.yahoo.com - June 12 at 4:48 PM |
| Morgan Stanley Reiterates "Buy" Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - June 11 at 2:02 PM |
| AstraZeneca plc (AZN) Receives Hold Rating from Shore Capital
www.americanbankingnews.com - June 8 at 11:02 PM |
| AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan - Nasdaq
www.nasdaq.com - June 8 at 9:32 PM |
| AstraZeneca to sell Zomig migraine drug rights - MarketWatch
www.marketwatch.com - June 7 at 8:04 AM |
| AstraZeneca sells migraine drug for up to $302 mln
finance.yahoo.com - June 7 at 8:04 AM |
| AstraZeneca plc (AZN) Given a GBX 4,500 Price Target at HSBC Holdings plc
www.americanbankingnews.com - June 6 at 7:28 AM |
| AstraZeneca plc's (AZN) "Overweight" Rating Reiterated at Barclays PLC
www.americanbankingnews.com - June 5 at 3:40 PM |
AstraZeneca plc (AZN) Chart for Thursday, July, 27, 2017
